# The latest science on cannabis has some good news and bad news > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-latest-science-on-cannabis-has-some-good-news-and-bad-news/ > **Published:** 2026-07-13T17:15:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:49:11-04:00 > **Clinical Summary:** Cannabinoid hyperemesis syndrome (CHS) in chronic heavy cannabis users: clinical features, diagnosis, and why cessation is essential for resolution. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyTHCMental HealthNeurologyCBDDosing Why This Matters Clinicians need to understand cannabinoid hyperemesis syndrome as a potential diagnosis in heavy cannabis users presenting with recurrent nausea and vomiting, since cessation remains the only effective treatment and misdiagnosis can lead to unnecessary testing and interventions. Knowledge of how different cannabis delivery methods affect cannabinoid bioavailability helps clinicians counsel patients on dose predictability and potential risks, particularly for those using high-potency products or frequent administration. This emerging clinical evidence should inform patient education and screening practices, especially as [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) becomes more normalized and patients may not spontaneously disclose consumption patterns. Clinical Summary # [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/): Mixed Clinical Evidence on Benefits and Risks Recent scientific evidence on cannabis reveals a complex clinical picture with both therapeutic promise and significant safety concerns. While cannabinoids demonstrate potential bioavailability and therapeutic applications, clinicians must be aware that chronic heavy [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) carries a documented risk for cannabinoid hyperemesis syndrome (CHS), a condition characterized by cyclic nausea and vomiting that can substantially impact patient quality of life and increase healthcare utilization. This emerging evidence suggests that cannabis is neither uniformly beneficial nor uniformly harmful, requiring individualized risk-benefit assessment for each patient based on their medical history, use patterns, and clinical presentation. Clinicians prescribing or counseling patients about cannabis should routinely screen for heavy use patterns and educate patients about CHS symptoms, particularly those using high-potency products or consuming daily. Patients considering [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) should understand that while potential benefits exist, long-term heavy use carries documented medical risks that warrant cautious, monitored approaches to cannabis use. Dr. Caplan’s Take “We’re seeing encouraging signals in the [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/), but I want to be clear that much of this work is still preliminary, and we need larger, longer human studies before we can make confident clinical recommendations. What concerns me in my practice is that while we explore potential benefits, we’re also documenting real harms like cannabinoid hyperemesis syndrome in heavy users, which tells me we need individualized risk assessment rather than broad statements about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/).” Clinical Perspective 💊 While emerging [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) shows potential therapeutic applications, clinicians should remain vigilant about cannabis-related harms, particularly cannabinoid hyperemesis syndrome in heavy long-term users, which presents as severe cyclic vomiting that can be refractory to standard antiemetics. The dose-dependent and individual variability in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/) complicates risk stratification, as factors like genetics, consumption patterns, and product potency all influence adverse outcomes. When counseling patients considering cannabis use, especially those with chronic nausea or vomiting, providers should clarify consumption frequency and quantity, educate about CHS as a serious possibility, and establish clear baseline symptoms to monitor. Given the evolving regulatory landscape and variable cannabinoid concentrations in commercial products, obtaining a detailed substance use history remains essential for differential diagnosis and risk assessment in patients presenting with unexplained hyperemesis. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20latest%20science%20on%20cannabis%20has%20some%20good%20news%20and%20bad%20news%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D69455)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D69455)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20latest%20science%20on%20cannabis%20has%20some%20good%20news%20and%20bad%20news%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D69455)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [New York Child Cannabis Poisonings Are Climbing: What the New State ER Report Means](https://cedclinic.com/pediatric-cannabis-poisoning-increase-new-york-er-report/) - [Why Did Ananda Developments Bounce On Its Latest Acquisition News?](https://cedclinic.com/why-did-ananda-developments-bounce-on-its-latest-acquisition-news/) - [Developments in Cannabis Withdrawal and Addiction Treatment](https://cedclinic.com/developments-in-cannabis-withdrawal-and-addiction-treatment/) 📰 Source: [https://www.washingtonpost.com/wellness/2026/07/13/good-news-bad-news-latest-science-cannabis/](https://www.washingtonpost.com/wellness/2026/07/13/good-news-bad-news-latest-science-cannabis/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).